Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65,348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Among authors: sun yu. Anticancer Res. 2020 May;40(5):2475-2479. doi: 10.21873/anticanres.14217. Anticancer Res. 2020. PMID: 32366391
A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J, Murata T, Tashiro Y, Higuchi T, Sugisawa N, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Hongo A, Nomura T, Saitoh W, Moriya T, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Among authors: sun yu. Anticancer Res. 2020 May;40(5):2509-2514. doi: 10.21873/anticanres.14221. Anticancer Res. 2020. PMID: 32366395
65,348 results
You have reached the last available page of results. Please see the User Guide for more information.